EPAX Confirms Its Oils Used In Latest Alzheimer's Study Conducted By Karolinska Institute

Main Category: Alzheimer's / Dementia
Also Included In: Neurology / Neuroscience;  Psychology / Psychiatry;  Clinical Trials / Drug Trials
Article Date: 28 Jun 2007 - 1:00 PDT

email to a friend   printer friendly   view / write opinions

Omega-3 fatty acids were again proven to help serious symptoms coinciding with the memory decline characteristic for Alzheimer's disease, according to a recent study conducted by Yvonne Freund-Levi, M.D. from Sweden's Karolinska Institute. EPAX AS, a world-leading supplier of highly concentrated omega-3 EPA/DHA fatty acids, confirmed its EPAX 1050 TG oil was used in the study.

Recently published in the International Journal of Geriatric Psychiatry, Freund-Levi's study was a randomised, double-blind, placebo-controlled clinical trial. It showed that carriers of a specific gene common to those with Alzheimer's disease who received the omega-3 supplements responded positively to the omega-3s in regards to agitation symptoms. Those without the gene showed an improvement in symptoms of depression.

"These findings are surely encouraging to the millions of people affected by Alzheimer's disease. This study helps demonstrate the many positive impacts of omega-3 fatty acids, whether one has specific health concerns or is simply looking to stay healthy. We are pleased that EPAX could play a role in this impressive clinical trial," said Bjorn Refsum, CEO of EPAX AS.

A previous study, published in the Oct. 2006 issues of Archives of Neurology, conducted by Freund-Levi found that patients with early-stage Alzheimer's disease given EPAX 1050 TG omega-3 fatty acids showed significant improvement in memory decline compared to the control group.

EPAX 1050 TG is specially formulated for cognitive health. All of EPAX's oils are indication-specific and in addition to cognitive health, oils are available to address cardiovascular health, mood and mind health, joint health, pre-and post-natal health and weight management.

About EPAX AS

EPAX AS is headquartered in Aalesund with a global sales office in Lysaker/Oslo, Norway. Its production facility in Aalesund is GMP-approved by the Norwegian Medicines Agency for the manufacturing of API products. All of EPAX's business efforts reflect the company's core commitment: Purity | Quality | Innovation. These values represent EPAX's commitment to offering products that are safe, pure and of consistent quality. EPAX AS offers concentrated omega-3 EPA/DHA oils in the business-to-business segment under the brand name EPAX, available in a wide range of top-quality formulas with different EPA/DHA concentrations and ratios focused on specific health conditions. EPAX is available in TG or EE versions.

http://www.epax.com